Results 251 to 260 of about 166,355 (310)

immunoHuMiX: A personalizable gut‐on‐chip model for unraveling human microbiome–immune interactions

VIEW, EarlyView.
The study introduces a personalized gut model that brings together human immune cells and intestinal cells to better mimic how the body interacts with microbes. This system successfully maintained both human cells and a 17‐strain probiotic community, showing consistent immune responses across different donors.
Charlotte De Rudder, Kacy Greenhalgh, Joanna Baginska, Camille Martin‐Gallausiaux, Léa Grandmougin, Rémy Villette, Mara Lucchetti, Bérénice Hansen, Marek Ostaszewski, Viacheslav A. Petrov, Koji Atarashi, Lena Weidert, Audrey Frachet Bour, Dominik Ternes, Javier Ramiro‐Garcia, Antoine Malabirade, Takeshi Tanoue, Marc Mac Giolla Eain, Elisabeth Letellier, Matthew Barrett, Jérôme Lacombe, Frederic Zenhausern, Coralie Guérin, Markus Ollert, Carole Seguin‐Devaux, Kenya Honda, Paul Wilmes   +26 more
wiley   +1 more source

The E3 ubiquitin ligase RNF180 modulates the EGFR/PI3K/AKT pathway to reduce cisplatin resistance in non-small cell lung cancer. [PDF]

Sci Rep
Song X, Jiang W, Wei H, Zhu Y, Shu J, Zhu C, Chen F.   +6 more
europepmc   +1 more source

Interventional oncology in children: Where are we now?

Journal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel, Fernando Gómez Muñoz   +1 more
wiley   +1 more source

Epithelial‑mesenchymal plasticity and cisplatin resistance in germ cell tumors: Mechanisms and emerging therapeutic strategies (Review). [PDF]

Int J Oncol
Gomes ESB, De Souza TM, Oliveira ALP, Bezerra AFSP, Cardoso IIV, Silva L, Lopes LF, Rosa MN, Pinto MT.   +8 more
europepmc   +1 more source

Factors Associated With Long‐Term Survivors With Epidermal Growth Factor Receptor Positive Non‐Small Cell Lung Cancer Treated With First or Second‐Generation Tyrosine Kinase Inhibitors: A Canadian Multi‐Center Cohort

Asia-Pacific Journal of Clinical Oncology, EarlyView.
In a multi‐center Canadian cohort of 577 patients with advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer treated with first/second‐generation TKIs, Asian ancestry and female sex predicted longer survival, while the L858R mutation predicted shorter survival.
Heather Halperin, Amanda J. W. Gibson, Ali Hussein, Mike Sung, Pascale Tomasini, Michelle Dean, Jennifer H. Law, Cheryl Ho, Vishal Navani, Natasha B. Leighl, Desiree Hao   +10 more
wiley   +1 more source

Clinofibrate Disrupts the SNORA80B/YTHDC1-Driven M6A Modification to Suppress Cholesterol Metabolism and Cisplatin Resistance in ESCC. [PDF]

Adv Sci (Weinh)
Yuan H, Ge G, Liu L, Hu S, Tian M, Nie Y, Zhao Z, Song Y.   +7 more
europepmc   +1 more source

Curcumol overcomes cisplatin resistance and rewires glycolysis-H3K9la-ORC6 axis to trigger ferroptosis in bladder cancer. [PDF]

Chin J Cancer Res
Zhang F, Yang Y, Zhang R, Hu H, Zhou C, Wang J, Wu R, Li E, Cho WC, Zhang D, Zhang Q, Feng D.   +11 more
europepmc   +1 more source

E2F7 promotes ESCC progression and cisplatin resistance through transcriptional activation of DVL3 and the Wnt signaling pathway. [PDF]

World J Surg Oncol
Li X, Chen L, Xu T, Yan Z.
europepmc   +1 more source

Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer: insights from preclinical models. [PDF]

Sci Rep
Tamburello M, Boldini C, Abate A, Salvi V, Valcamonico F, Laganà M, Cosentini D, Suardi NR, Mirabella G, Altieri B, Sigala S.   +10 more
europepmc   +1 more source

Mechanistic study of the role of emodin in targeting and inhibiting the Rap1 signaling pathway to regulate epithelial-mesenchymal transition and reverse cisplatin resistance in hepatocellular carcinoma. [PDF]

Transl Cancer Res
Zhang R, Jiao Y, Wang S, Wang L, Leng Y, Xiong Z, Yang M.   +6 more
europepmc   +1 more source